Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in High-Risk Superficial Bladder Cancer
NCT01118351Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2008
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in Transitional cell carcinoma of the bladder (TCC), sponsored by Case Comprehensive Cancer Center. Started Oct 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
Transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NCT01118351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118351.